This article was originally published in The Gray Sheet
U.S. shipments of the Discovery and Meridian next-generation pacemaker families are scheduled to begin May 5, following receipt of FDA approval April 30, the firm says. Approved via premarket approval application supplement to Guidant's Vigor pacemaker, the device families include single- and dual-chamber models with adaptive-rate pacing and advanced diagnostics. The devices incorporate Quick Start, Quick Check and Quick Notes features, designed to allow clinicians "to easily and quickly perform a comprehensive set of automatic tests and follow-up device operations," and provide a printout summarizing data needed for informed patient management, Guidant explains. The Discovery line also has the ability to store and display "diagnostic-quality atrial and ventricular electrograms simultaneously." The devices debuted in Europe in mid-March
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.